The quantum race will be won by whoever owns the chokepoints.

IBM surged 7% on June 1 after committing more than $10 billion to quantum computing over five years — R&D, capex, manufacturing scale, ecosystem partnerships, and M&A — funding a roadmap to IBM Quantum Starling, the targeted first large-scale fault-tolerant system, by 2029. The rotation was immediate and mechanical: IONQ fell 4% on the day and extended losses to 9.7% by June 9 as institutional capital concentrated in IBM's enterprise distribution, government-grant backstop (part of the $2B in U.S. federal quantum awards announced May 21), and established commercial relationships over the cash-burning pure-play stack. IBM's May performance — up 32%, its best monthly gain in nearly 24 years — had already signaled the market's preference before the formal commitment; the June announcement confirmed it.

Coherent reached an all-time high of $440 on June 3, sustained by a $2B NVIDIA strategic partnership and record Q3 FY2026 revenue of $1.81 billion (+20.5% year-over-year) with non-GAAP gross margin expanding to 39.6%, before retracing sharply to $349 by June 10 on profit-taking after a 372% twelve-month run. The pullback matters for the lasers-and-photonics chokepoint: COHR's quantum-optics laser portfolio — the narrow-linewidth sources, Sapphire XT visible lasers, and cold-atom optics that trapped-ion and neutral-atom machines depend on — is a secondary segment behind AI optical networking, which means quantum photonics exposure rides and falls with datacenter capex sentiment rather than quantum program milestones. The six-inch InP capacity ramp (now doubling by end of Q4 FY2026, one quarter ahead of plan) reinforces COHR's AI-first valuation; the quantum optics thesis accrues over a longer horizon. COHR Q4 FY2026 earnings on August 13 will be the next test of whether margin expansion held.

The DARPA Quantum Benchmarking Initiative Stage B-to-Stage C down-select decision (expected by end of November 2026) remains the year's hardest credibility test for the pure-play stack: DARPA's verdict on which of 11 Stage B roadmaps — including IonQ's — are credible for utility-scale quantum by 2033 is the closest thing to a government-graded falsification event in the sector, as Rigetti's initial Stage B miss showed. Watch IonQ's Q2 2026 earnings on August 12 for progress against the $470M remaining performance obligation and whether the SkyWater Technology acquisition integration is tracking; for Rigetti, the £100M UK deployment and the 99.5% median two-qubit fidelity target on the 108-qubit Cepheus system are the hardware markers that would justify re-rating. Keysight (Q3 FY2026 earnings pending) and FormFactor are the control-electronics names to watch for any signal on cryo-CMOS test rack demand.